Christopher Fenimore
Executive Vice President, Finance And Chief Financial Officer
Regeneron Pharmaceuticals, Inc. · REGN
$7M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A filed April 24, 2026. Prior years are from that filing's three-year table.
Catalog as of September 15, 2026. Not a live market feed.
- Salary
- $725K
- Stock Awards
- $2.2M
- Option Awards
- $3.3M
- Incentives
- $721K
- Other
- $40K
Compensation History
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $725,000 | $2,199,751 | $6,985,364 |
| 2024 | $660,000 | $1,999,319 | $6,268,252 |
Current Position
- Title
- Executive Vice President, Finance And Chief Financial Officer
- Ticker
- REGN · NASDAQ
- Fiscal Year
- 2025
SEC Sources
Fiscal years below are columns from the latest DEF 14A Summary Compensation Table (filed April 24, 2026), not separate historical filings.
| Fiscal Year | Source |
|---|---|
| 2025 | View SEC filing |
| 2024 | View SEC filing |
Accession 0001308179-26-000340.
Other Regeneron Executives
Leonard S. Schleifer
M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
Regeneron · REGN
$7.3M
FY 2025 · DEF 14A
George D. Yancopoulos
M.D., Ph.d.board Co-Chair, President And Chief Scientific Officer
Regeneron · REGN
$6.9M
FY 2025 · DEF 14A
Daniel P. Van Plew
Executive Vice President And General Manager, Industrial Operations And Product Supply
Regeneron · REGN
$8.8M
FY 2025 · DEF 14A
Andrew J. Murphy
Ph.d.executive Vice President, Co-Chief Scientific Officer
Regeneron · REGN
$8.5M
FY 2025 · DEF 14A
Joseph J. La Rosa
Executive Vice President, General Counsel And Secretary10
Regeneron · REGN
$7.5M
FY 2025 · DEF 14A